ProCE Banner Activity

Incorporating Long-Acting Growth Hormone Therapy Into Practice

Clinical Thought

Dr Andrew Hoffman—a leading expert in growth hormone therapy—shares his strategies for incorporating long-acting growth hormone therapy into practice to improve patient compliance and outcomes, including an extensive description of existing therapies, common barriers, and advice for HCPs.

Released: July 26, 2023

Expiration: July 26, 2024

Share

Faculty

Andrew Hoffman

Andrew Hoffman, MD

Professor of Medicine
Stanford University School of Medicine
Stanford, California

Provided by

Provided by Clinical Care Option, LLC in partnership with Endocrine Society

ProCE Banner
ProCE Banner

Supporters

This activity is supported by an educational grant from Novo Nordisk.

Novo Nordisk

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply the appropriate diagnostic tests to a patient with a high suspicion of GHD

  • Evaluate the efficacy and safety of long-acting growth hormone therapies in pediatric and adult patients with GHD

  • Develop comprehensive treatment plans for patients with GHD, including agent selection, dosing, and monitoring

  • Implement strategies to improve treatment adherence and transitions of care for patients with GHD

Disclosure

Primary Author

Andrew Hoffman, MD

Professor of Medicine
Stanford University School of Medicine
Stanford, California

Andrew Hoffman, MD: consultant/advisor/speaker: Ascendis, Novo Nordisk.